Format

Send to

Choose Destination
J Neuroimmunol. 2005 Aug;165(1-2):166-71.

Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes.

Author information

1
Service of Neurology, Hospital Clinic, Universitat de Barcelona, and Institut d' Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Villarroel 170, Barcelona 08036, Spain. fgraus@clinic.ub.es

Abstract

We describe a new antibody, called anti-glial nuclear antibody (AGNA), in patients with paraneoplastic neurological syndromes (PNS) and small-cell lung carcinoma (SCLC). AGNA was initially identified in 24 sera of our archives by immunohistochemistry on rat cerebellum. AGNA positive sera showed a characteristic nuclear staining of the Bergmann glia in the Purkinje cell layer. Immunoblots and probing a cerebellar expression library with AGNA sera did not identify the antigen. Twenty of the 24 patients with AGNA had PNS and all but two had lung cancer. AGNA was identified in 13/113 (11.5%) patients with SCLC compared with 0/122 with other types of cancer (p<0.0001). The frequency of AGNA was not higher than expected for the presence of SCLC in the different PNS subtypes except in LEMS (p=0.0002). AGNA was present in 13/30 (43%) of LEMS patients with SCLC, compared with 0/19 of LEMS patients without cancer (p=0.0006). We conclude that the recognition of AGNA is helpful since this antibody is found in PNS associated with SCLC, particularly LEMS, in which other onconeural antibodies are absent.

PMID:
15949849
PMCID:
PMC2586939
DOI:
10.1016/j.jneuroim.2005.03.020
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center